DDInter1491 DDInter1026
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Calaspargase pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Citalopram
Citalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Pomalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Larotrectinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Citalopram (Compound) and Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Pomalidomide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Larotrectinib
Pomalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib